Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gaßler N, Drescher R, Freesmeyer M, Malouhi A, Bürckenmeyer F, Aschenbach R, Teichgräber U, Kögler C, Vogt M, Hofmann GO, Hochhaus A.
Schrenk KG, et al. Among authors: vogt m.
J Cancer Res Clin Oncol. 2023 Aug;149(9):5493-5496. doi: 10.1007/s00432-022-04496-y. Epub 2022 Dec 5.
J Cancer Res Clin Oncol. 2023.
PMID: 36469155
Free PMC article.